AZN vs NVS
AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | AZN | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $169.73 | $153.08 | |
| Market cap as of 2026-07-23 | $193.7B | $229.2B | |
| P/E as of 2026-07-23 | 24.93 | 22.11 | NVS lower |
| PEG as of 2026-07-23 | 2.64 | 3.66 | AZN lower |
| Net margin as of 2026-07-23 | +17.2% | +22.5% | NVS higher |
| Gross margin as of 2026-07-23 | +81.4% | +75.0% | AZN higher |
| Operating margin as of 2026-07-23 | +23.7% | +29.9% | NVS higher |
| ROE as of 2026-07-23 | +22.3% | +29.9% | NVS higher |
| ROA as of 2026-07-23 | +9.1% | +11.1% | NVS higher |
| Debt / equity as of 2026-07-23 | 0.72 | 1.18 | AZN lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | +3.3% | AZN higher |
| Dividend yield as of 2026-07-23 | +1.9% | +3.0% | NVS higher |
| Beta as of 2026-07-23 | 1.38 | 1.17 | |
| 1-year return as of 2026-07-22 close | +17.0% | +35.8% | NVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.